| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/02/2002 | WO2002005822A3 Compositions containing therapeutically active components having enhanced solubility |
| 05/02/2002 | WO2002002091A3 Methods and compositions for the treatment of alcoholism and alcohol dependence |
| 05/02/2002 | WO2001098361A3 Agonist anti-trk-c monoclonal antibodies |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001097785A3 Basic copolymers for the treatment of prion-related-disease |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001094586A3 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 05/02/2002 | WO2001093863A3 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
| 05/02/2002 | WO2001092282A3 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/02/2002 | WO2001089489A3 Transdermal application of active agents directly via the carotid artery |
| 05/02/2002 | WO2001089450A3 Treating musculoskeletal disorders using lp85 and analogs thereof |
| 05/02/2002 | WO2001085165A3 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 05/02/2002 | WO2001083555A3 Pain signaling molecules |
| 05/02/2002 | WO2001081298A3 Cyclic carboxylic acids as integrin antagonists |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001070771A3 Acute neuronal induced calcium binding protein type 1 ligand |
| 05/02/2002 | WO2001070733A3 Di-substituted iminoheterocyclic compounds |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001043757A3 Composition comprising ingredients of panax ginseng and ginko biloba |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | WO2000075365A9 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 05/02/2002 | US20020053093 By use of biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 05/02/2002 | US20020052693 Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 05/02/2002 | US20020052512 Diaminopropionic acid derivatives |
| 05/02/2002 | US20020052504 N-((2-cyclopropoxy-5-(1H-tetrazol-1-))phenyl)methyl-2-(4 -phenyl)piperidin-3-amine and derivatives; in particular as neurokinin-1 receptor antagonists; analgesics; migraines; antiinflammatory, anxiolytic, emetic agents; antidepressants |
| 05/02/2002 | US20020052495 Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor |
| 05/02/2002 | US20020052477 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
| 05/02/2002 | US20020052475 Cytokines for use in the treatment of autoimmune disease, inflammation, arthritis and multiple sclerosis |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052418 Administering a derivative of a valproic acid amide or a 2-valproenic acid amide to the patient for treating pain and headache disorders |
| 05/02/2002 | US20020052409 Compounds and methods for treating mitochondria-associated diseases |
| 05/02/2002 | US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor |
| 05/02/2002 | US20020052405 Treating obesity, anxiety disorder, post-traumatic stress disorder, premenstrual syndrome, attention deficit disorder, Tourette syndrome, bulimia nervosa or Shy Drager Syndrome by administering a hydroxycycloalkanephenethyl amine |
| 05/02/2002 | US20020052401 Benzophenones and sulfones as inhibitors of glycine uptake |
| 05/02/2002 | US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052393 Benzanilides as potassium channel openers |
| 05/02/2002 | US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents. |
| 05/02/2002 | US20020052391 Tetrahydroquinoline derivatives as glycine antagonists |
| 05/02/2002 | US20020052389 Quinuclidine-substituted aryl compounds for treatment of disease |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052385 Administering 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline to a patient suffering from or at risk of developing ALS in order to reduce symptoms or delay onset of ALS. |
| 05/02/2002 | US20020052383 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. |
| 05/02/2002 | US20020052382 R-hydroxynefazodone |
| 05/02/2002 | US20020052373 D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. |
| 05/02/2002 | US20020052372 Using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins |
| 05/02/2002 | US20020052371 Neuropeptide Y receptor antagonist; treatment of bulimia, obesity or diabetes; e.g., spiro(isobenzofuran-1-(3H),4'-pyridine)-1'-carboxamides |
| 05/02/2002 | US20020052365 Selective anxiolytic therapeutic agents |
| 05/02/2002 | US20020052364 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors |
| 05/02/2002 | US20020052362 CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders |
| 05/02/2002 | US20020052359 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds |
| 05/02/2002 | US20020052355 Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds |
| 05/02/2002 | US20020052352 Treating a malignant tumor, like a melanoma, using plant-derived compounds |
| 05/02/2002 | US20020052351 Novel medical use for tachykinin antagonists |
| 05/02/2002 | US20020052350 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 05/02/2002 | US20020052349 p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052341 Bupropion metabolites and methods of their synthesis and use |
| 05/02/2002 | US20020052340 Treating disorders ameliorated by inhibition of neuronal monoamine reuptake, such as erectile dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. |
| 05/02/2002 | US20020052339 Methods for treatment of impulse control disorders |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020052319 Topical anesthetic/opioid formulations and uses thereof |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 05/02/2002 | US20020052315 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/02/2002 | US20020052311 Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| 05/02/2002 | US20020052022 Molecular cloning of a chemokine like 7TMR (AXOR87) |
| 05/02/2002 | US20020051988 Inhibition of amyloid protein bnding to neuronal receptor; obtain cell, incubate with modulator, monitor amyloid protein activity |
| 05/02/2002 | US20020051771 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201764A2 Assays for identifying phosphatase inhibitors |
| 05/02/2002 | EP1201754A1 Apoptosis-associated factor |
| 05/02/2002 | EP1201663A1 Process for producing dibenzothiazepine derivatives |
| 05/02/2002 | EP1201660A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201649A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201268A2 Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors |
| 05/02/2002 | EP1201244A2 Anti-depressant, stress suppressor and mood improver |
| 05/02/2002 | EP1201241A2 Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
| 05/02/2002 | EP1201240A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/02/2002 | EP1201235A1 Neuropathy improvers containing nitrogenous compounds as the active ingredient |
| 05/02/2002 | EP1201136A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200616A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200586A2 Human nervous system-associated proteins |
| 05/02/2002 | EP1200584A1 Splice variants of cd40-receptor |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200569A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |